One very small detail: you left "research" out of CHGR in your signature
Marylyn D Ritchie Ph.D. Assistant Professor of Molecular Physiology &
Biophysics, Center for Human Genetics, Vanderbilt University
Marylyn Ritchie wrote:
>Pacific Symposium on Biocomputing
>The Big Island of Hawaii, January 4-8, 2005
>Computational Approaches for Pharmacogenomics
>Call for Papers and Participation
>Session on Computational Approaches for Pharmacogenomics
>Pharmacogenomics is a fascinating, emerging area of biomedical research.
>This area is defined as the intersection between pharmacology and genetics.
>There is evidence that an individuals' response to drug treatment can be
>explained, in part, by their genetic variation in certain areas of the
>genome. Pharmacogenomics holds the promise for individualized medicine,
>where drugs might one day be tailor-made for individuals and adapted to each
>person's own genetic makeup. Environmental factors including diet, age, and
>lifestyle can influence a person's response to medicines, but understanding
>an individual's genetic makeup is thought to be the key to creating
>personalized drugs with greater efficacy and safety.
>Pharmacogenomics combines traditional pharmaceutical sciences such as
>biochemistry with annotated knowledge of genes, proteins, and single
>nucleotide polymorphisms. With the sequencing of the human genome near
>completion, the ability to obtain information about an individual's entire
>genome is upon us. This will allow for the detection of genetic variations
>associated with drug response and adverse outcomes on a full genomic scale.
>Technology has advanced greatly in the area of experimental procedures used
>to explore pharmacogenomics questions. The major challenges now are
>developing the statistical and computational capacity to store, manage,
>analyze and interpret the wealth of data being generated.
>This session is designed to explore the current state-of-the-art research
>taking place in bioinformatics, biostatistics, and computational genetics to
>develop tools for the handling of all the pharmacogenomics data being
>generated. The goal of this session is the presentation and discussion of
>new research, algorithms, and methods for the management and analysis of
>pharmacogenomics data. We intend for this session to bring together
>scientists from pharmacology, genetics, statistics, and computational
>biology/bioinformatics to share their efforts in pharmacogenomics.
>Submission topics can include but are not limited to:
>- database design and implementation
>- data sharing among pharmacogenomics centers
>- statistical analysis of pharmacogenomics data
>- abstracting and validating clinical phenotypes
>- statistical and computational method development
>- real data applications.
>General Information on PSB
>The Pacific Symposium on Biocomputing (PSB 2005) is an international,
>multidisciplinary conference for the presentation and discussion of current
>research in the theory and application of computational methods in problems
>of biological significance. PSB 2005 will be held January 4-8, 2005 at the
>Fairmont Orchid on the Big Island of Hawaii. Tutorials will be offered
>prior to the start of the conference.
>PSB has been designed to be responsive to the need for critical mass in
>sub-disciplines within biocomputing. For that reason, it is the only
>meeting whose sessions are defined dynamically each year in response to
>specific proposals. PSB sessions are targeted to provide a forum for
>publication and discussion of research in biocomputing’s “hot topics”. In
>this way, PSB provides an early forum for serious examination of emerging
>methods and approaches in a rapidly changing field. More information on the
>conference can be obtained from the conference web page:
>- Submissions are due July 16, 2004
>- Decisions are announced August 30, 2004
>- Camera ready copy due September 20, 2004
>- Poster abstracts due November 1, 2004
>PSB will publish accepted full papers in an archival proceedings volume
>indexed in MEDLINE. All submissions will be peer-reviewed. A limited number
>of submissions will be selected for oral presentation. Poster abstracts
>will be submitted separately from the conference proceedings. All papers
>must be submitted to russ.altman@... in electronic format. The
>file formats we accept are: postscript (*.ps), adobe acrobat (*.pdf), and
>Microsoft Word (*.doc). Attached files should be names with the last name of
>the first author (e.g. altman.ps, altman.pdf, or altman.doc). Hardcopy
>submissions or unprocessed TEX or LATEX files will be rejected without
>Each paper must be accompanied by a cover letter. The cover letter must
>state the following:
>- The email address of the corresponding author
>- The specific PSB session that should review the paper or abstract
>- The submitted paper contains original, unpublished results, and is
>not currently under consideration elsewhere.
>- All co-authors concur with the contents of the paper.
>Submitted papers are limited to twelve (12) pages in our publication format.
>Please format your paper according to instructions found at
>ftp://ftp-smi.stanford.edu/pub/altman/psb. If figures can not be easily
>resized and placed precisely in the text, then it should be clear with
>appropriate modifications, the total manuscript length would be within the
>page limit. Color pictures can be printed at the expense of the author.
>The fee is $500 per page of color pictures, and is payable at the time of
>Marylyn D Ritchie Ph.D. Assistant Professor of Molecular Physiology &
>Biophysics, Center for Human Genetics, Vanderbilt University
>Michelle W Carrillo Ph.D. Head Scientific Curator PharmGKB, Stanford
>Russell Wilke MD, Ph.D. Head of Pharmacogenetics, Marshfield Clinic
>Research Foundation wilke.russell@...
>Yahoo! Groups Links
I have suffered from being misunderstood, but I would
have suffered a hell of a lot more if I had been understood.
-Clarence Darrow, lawyer and author (1857-1938)